Is Auvelity the new FDA-approved medication for treating major depressive disorder in adults?
Auvelity is a newer oral medication approved by the FDA for major depressive disorder (MDD) in adults. It combines two drugs: dextromethorphan, which affects glutamate signaling in the brain, and bupropion, which helps maintain dextromethorphan levels. This approval offers an additional treatment option for adults with MDD.
What the research says
The FDA approved Auvelity (dextromethorphan/bupropion) for the treatment of major depressive disorder in adults, as stated in the prescribing information 4. This approval is based on clinical studies showing its efficacy and safety. Auvelity works through a different mechanism than traditional antidepressants: dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, targeting the glutamate system, which is a newer approach in depression treatment 49. Bupropion is included to inhibit the enzyme that breaks down dextromethorphan, increasing its levels in the body 4. This combination is part of a class of glutamatergic modulators, which also includes esketamine (Spravato), another FDA-approved treatment for depression 9. While Auvelity is approved for MDD, other treatments like cognitive-behavioral therapy and aerobic exercise also have evidence supporting their use in depression 38.
What to ask your doctor
- Is Auvelity a good option for my type of depression, especially if other medications haven't worked?
- How does Auvelity differ from other antidepressants I've tried, and what side effects should I expect?
- Are there any interactions between Auvelity and my current medications or health conditions?
- How long does it typically take to see improvement with Auvelity, and what dose is right for me?
- Should I consider combining Auvelity with therapy or other non-medication treatments for better results?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.